Overview

Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants

Status:
Completed

Trial end date:
2019-04-10

Target enrollment:

Participant gender:

Summary

This Phase 1, open-label, single-sequence, non-randomized, multiple-dose, crossover pharmacokinetic study is a single site study in the United States and will be conducted to assess the effect of a CYP1A2 inducer (omeprazole 40 mg once daily [QD]) on the pharmacokinetics of anagrelide (1 mg) when administered concurrently in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Shire

Treatments:

Anagrelide
Omeprazole